To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Phase 2 Completed 33 enrolled River 2 Renal Corp. International HealthCare, LLC · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Timeline

Start: 2024-03-01
Primary completion: 2024-11-04
Completion: 2024-11-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	R2R01	Unknown	5 mg	Subcutaneous
Subject	R2R01	Unknown	7.5 mg	Subcutaneous
Subject	R2R01	Unknown	10 mg	Subcutaneous

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Summary

Timeline

Drugs

Indications